Literature DB >> 28464471

Chemical activation of adenylyl cyclase Rv1625c inhibits growth of Mycobacterium tuberculosis on cholesterol and modulates intramacrophage signaling.

Richard M Johnson1, Guangchun Bai2, Christopher M DeMott3, Nilesh K Banavali1,4, Christine R Montague5, Caroline Moon5, Alexander Shekhtman3, Brian VanderVen5, Kathleen A McDonough1,4.   

Abstract

Mycobacterium tuberculosis (Mtb) uses a complex 3', 5'-cyclic AMP (cAMP) signaling network to sense and respond to changing environments encountered during infection, so perturbation of cAMP signaling might be leveraged to disrupt Mtb pathogenesis. However, understanding of cAMP signaling pathways is hindered by the presence of at least 15 distinct adenylyl cyclases (ACs). Recently, the small molecule V-58 was shown to inhibit Mtb replication within macrophages and stimulate cAMP production in Mtb. Here we determined that V-58 rapidly and directly activates Mtb AC Rv1625c to produce high levels of cAMP regardless of the bacterial environment or growth medium. Metabolic inhibition by V-58 was carbon source dependent in Mtb and did not occur in Mycobacterium smegmatis, suggesting that V-58-mediated growth inhibition is due to interference with specific Mtb metabolic pathways rather than a generalized cAMP toxicity. Chemical stimulation of cAMP production by Mtb within macrophages also caused down regulation of TNF-α production by the macrophages, indicating a complex role for cAMP in Mtb pathogenesis. Together these studies describe a novel approach for targeted stimulation of cAMP production in Mtb, and provide new insights into the myriad roles of cAMP signaling in Mtb, particularly during Mtb's interactions with macrophages.
© 2017 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28464471      PMCID: PMC5499149          DOI: 10.1111/mmi.13701

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  75 in total

Review 1.  Immunology of tuberculosis.

Authors:  J L Flynn; J Chan
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Eukaryotic-like adenylyl cyclases in Mycobacterium tuberculosis H37Rv: cloning and characterization.

Authors:  S K Reddy; M Kamireddi; K Dhanireddy; L Young; A Davis; P T Reddy
Journal:  J Biol Chem       Date:  2001-06-28       Impact factor: 5.157

Review 3.  Role of Pseudomonas aeruginosa type III effectors in disease.

Authors:  Joanne Engel; Priya Balachandran
Journal:  Curr Opin Microbiol       Date:  2009-01-23       Impact factor: 7.934

4.  Filamin A is a phosphorylation target of membrane but not cytosolic adenylyl cyclase activity.

Authors:  Sarah L Sayner; Ron Balczon; Dara W Frank; Dermot M F Cooper; Troy Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-04-08       Impact factor: 5.464

5.  Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges.

Authors:  K Vanommeslaeghe; E Prabhu Raman; A D MacKerell
Journal:  J Chem Inf Model       Date:  2012-11-28       Impact factor: 4.956

6.  Identification of a Mycobacterium tuberculosis putative classical nitroreductase gene whose expression is coregulated with that of the acr aene within macrophages, in standing versus shaking cultures, and under low oxygen conditions.

Authors:  Anjan Purkayastha; Lee Ann McCue; Kathleen A McDonough
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

7.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

Authors:  J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

8.  Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105.

Authors:  Estelle A Wall; Joelle R Zavzavadjian; Mi Sook Chang; Baljinder Randhawa; Xiaocui Zhu; Robert C Hsueh; Jamie Liu; Adrienne Driver; Xiaoyan Robert Bao; Paul C Sternweis; Melvin I Simon; Iain D C Fraser
Journal:  Sci Signal       Date:  2009-06-16       Impact factor: 8.192

Review 9.  Cyclic AMP: master regulator of innate immune cell function.

Authors:  Carlos H Serezani; Megan N Ballinger; David M Aronoff; Marc Peters-Golden
Journal:  Am J Respir Cell Mol Biol       Date:  2008-03-06       Impact factor: 6.914

10.  Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas.

Authors:  Ciaran Skerry; Jamie Harper; Mariah Klunk; William R Bishai; Sanjay K Jain
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

View more
  10 in total

1.  GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.

Authors:  Eric L Nuermberger; Maria Santos Martínez-Martínez; Olalla Sanz; Beatriz Urones; Jorge Esquivias; Heena Soni; Rokeya Tasneen; Sandeep Tyagi; Si-Yang Li; Paul J Converse; Helena I Boshoff; Gregory T Robertson; Gurdyal S Besra; Katherine A Abrahams; Anna M Upton; Khisimuzi Mdluli; Gary W Boyle; Sam Turner; Nader Fotouhi; Nicholas C Cammack; Juan Miguel Siles; Marta Alonso; Jaime Escribano; Joel Lelievre; Joaquin Rullas-Trincado; Esther Pérez-Herrán; Robert H Bates; Gareth Maher-Edwards; David Barros; Lluís Ballell; Elena Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2022-05-24       Impact factor: 5.938

Review 2.  More than cholesterol catabolism: regulatory vulnerabilities in Mycobacterium tuberculosis.

Authors:  Amber C Bonds; Nicole S Sampson
Journal:  Curr Opin Chem Biol       Date:  2018-06-12       Impact factor: 8.822

Review 3.  Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis.

Authors:  Sabine Ehrt; Dirk Schnappinger; Kyu Y Rhee
Journal:  Nat Rev Microbiol       Date:  2018-08       Impact factor: 60.633

Review 4.  Cholesterol and fatty acids grease the wheels of Mycobacterium tuberculosis pathogenesis.

Authors:  Kaley M Wilburn; Rachael A Fieweger; Brian C VanderVen
Journal:  Pathog Dis       Date:  2018-03-01       Impact factor: 3.166

5.  Metabolomics reveals that the cAMP receptor protein regulates nitrogen and peptidoglycan synthesis in Mycobacterium tuberculosis.

Authors:  Yi Liu; Sonia Rebollo-Ramirez; Gerald Larrouy-Maumus
Journal:  RSC Adv       Date:  2020-07-10       Impact factor: 4.036

6.  cAMP is an allosteric modulator of DNA binding specificity in cAMP receptor protein from Mycobacterium tuberculosis.

Authors:  Fernanda Gárate; Stephen Dokas; Maria Fe Lanfranco; Clare Canavan; Irina Wang; John J Correia; Rodrigo A Maillard
Journal:  J Biol Chem       Date:  2021-02-25       Impact factor: 5.157

7.  Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis.

Authors:  Kaley M Wilburn; Christine R Montague; Bo Qin; Ashley K Woods; Melissa S Love; Case W McNamara; Peter G Schultz; Teresa L Southard; Lu Huang; H Michael Petrassi; Brian C VanderVen
Journal:  PLoS Pathog       Date:  2022-02-08       Impact factor: 6.823

8.  Structure of Mycobacterium tuberculosis Cya, an evolutionary ancestor of the mammalian membrane adenylyl cyclases.

Authors:  Ved Mehta; Basavraj Khanppnavar; Dina Schuster; Ilayda Kantarci; Irene Vercellino; Angela Kosturanova; Tarun Iype; Sasa Stefanic; Paola Picotti; Volodymyr M Korkhov
Journal:  Elife       Date:  2022-08-18       Impact factor: 8.713

9.  AbmR (Rv1265) is a novel transcription factor of Mycobacterium tuberculosis that regulates host cell association and expression of the non-coding small RNA Mcr11.

Authors:  Roxie C Girardin; Guangchun Bai; Jie He; Haixin Sui; Kathleen A McDonough
Journal:  Mol Microbiol       Date:  2018-10-21       Impact factor: 3.501

Review 10.  Mycobacterial Control of Host Mitochondria: Bioenergetic and Metabolic Changes Shaping Cell Fate and Infection Outcome.

Authors:  Krishnaveni Mohareer; Jayashankar Medikonda; Govinda Raju Vadankula; Sharmistha Banerjee
Journal:  Front Cell Infect Microbiol       Date:  2020-09-30       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.